 Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile. Minocycline effects the glutaminergic system, through inhibition of neuronal nitric oxide synthase nNOS and blocking of nitric oxide NO- induced neurotoxicity Du et al, 1998; Jiang et al., 2005, and thus has been suggested as a potential treatment for schizophrenia. One published study Levkovitz, Mendlovich et al. 2010, and another, unpublished study by Bill Deakin found that add-on treatment of 200mgd of Minocycline was beneficial for symptoms and cognition in schizophrenia, and a study by Miayoka et al Miyaoka, Yasukawa et al. 2008 administered open-label 450 mgday Minocycline, and found improvement on positive symptoms. 